|Awarded On||May 18, 2016|
|Title||An unlikely therapeutic target for malignant bone disease: Dkk-1 activates a stress resistance mechanism in bone tumor cells|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Texas A&M University System Health Science Center|
|Principal Investigator/Program Director||Carl A Gregory|
|Cancer Sites||Bone, Breast, Myeloma, Prostate|
About 35% of the 700,000 newly diagnosed cancers in the US will involve serious bone complications. Malignant bone disease (MBD) occurs when tumors initiate in bone or travel to it from other tissues. When they populate bone, tumor cells have a tendency to cause catastrophic damage in the form of osteolytic lesions (OLs). OLs are holes in bone caused by tumors that frequently cause fractures, pain and provide an ideal environment for tumor growth. MBD is typically treated by chemotherapy in an attempt to kill the tumor while bone destruction can be slowed with drugs. Even with these treatments, OLs generally fail to heal, providing an effective environment for tumor survival. The key to effe...